10:11 AM EST - Avant Technologies Inc : Along with its Joint Venture partner, Ainnova Tech, Inc., today announced that Ainnova is refining its patient recruitment strategy for the Company's planned clinical trial for its Vision AI platform in the early detection of diabetic retinopathy. Ainnova will work directly with Fortrea, a globally recognized Contract Research Organization renowned for its expertise in ophthalmology studies and medical device trials, following the guidance the Company received from its recent meeting with the U.S. Food and Drug Administration. Avant Technologies Inc
shares O.AVAI are trading -$0.04 at $0.50.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=AVAI&qmodStoryID=5674202876400104
